What's more, anti-CD147 monoclonal antibody can inhibit the occurrence and development of pancreatic cancer, suggesting that anti-CD147 monoclonal antibody has potential clinical value in drug-resistant recurrence of pancreatic cancer 32. Here, BSG is linked to pancreatic neoplasm.